Why Soleno Therapeutics Stock Rocketed Higher on Monday

By Eric Volkman – Apr 6, 2026 at 4:20PM ESTKey PointsThe deal isn't cheap; the biotech is changing hands at a 34% premium.It gives the buyer a unique product that was FDA-approved barley over a year ago.On news that Soleno Therapeutics (SLNO +32.31%) has agreed to be acquired, investors piled into the company's shares on Monday. This left the commercial-stage biotech with a juicy 32% gain on the day's trading session. Biotech buyout That morning, Soleno and its peer biotech, Neurocrine Biosciences (NBIX +0.62%), announced that they had signed a definitive agreement under which Neurocrine would acquire Soleno. The deal, valued at $2.9 billion, will see Neurocrine pay $53 per share in an all-cash transaction to own Soleno. Image source: Getty Images. Soleno is a rare-disease specialist who earned its first approval from the Food and Drug Administration (FDA) in March 2025. This nod was for Vykat XR, a medicine that treats hyperphagia (excessive hunger) arising from the genetic disorder Prader-Willi Syndrome. In their joint press release on the acquisition, the two companies quoted Neurocrine CEO Kyle Gano as saying that it "will advance Neurocrine's mission to deliver life-changing treatments while accelerating our revenue growth and portfolio diversification strategy." The deal is subject to the tender of at least a majority of Soleno's outstanding shares -- which shouldn't be an issue, given that the offering price is 34% higher than the stock's level last Thursday. It has been approved by the boards of directors of both companies. The two expect the acquisition to close within 90 days. ExpandNASDAQ: SLNOSoleno TherapeuticsToday's Change(32.31%) $12.76Current Price$52.25Key Data PointsMarket Cap$2.0BDay's Range$52.15 - $52.3852wk Range$29.43 - $90.32Volume58MAvg Vol1.7MGross Margin98.32% That's one unique asset The hefty double-digit premium shows how eager Neurocrine was to get its hands on Soleno, particularly following last year's FDA green light for Vykat XR (the only treatment in this country approved for hyperphagia associated with Prader-Willi). As often happens in these situations, Soleno's price zoomed to nearly the buyout price (it currently sits at $52.25). There's some room for arbitrage, then, but for the most part, Soleno's days as a stand-alone stock are ticking down fast. Anyone who hasn't sold out yet should do so and book their profits.Read NextApr 6, 2026 •By Josh Kohn-LindquistStock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout AgreementApr 4, 2026 •By Parkev Tatevosian, CFAUnitedHealth Stock Analysis: Generational Buying Opportunity or a Falling Knife to Avoid?Apr 4, 2026 •By Justin PopeEli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug FightApr 4, 2026 •By Lee SamahaBetter Healthcare Stock to Own in a Recession: Defensive or Growth?Apr 6, 2026 •By Eric VolkmanWhy Sandisk Stock Topped the Market TodayApr 6, 2026 •By Jeremy BowmanA Strong Jobs Report Usually Moves Markets.

Here Is Why Oil at $110 and a Closed Strait of Hormuz Are Drowning Out the Good NewsAbout the AuthorEric Volkman is a contributing Motley Fool finance and stock market analyst. Previously, Eric was an equities analyst at European investment bank Raiffeisen Capital and Investment. He’s also been a freelance finance writer since 1995. He studied at Susquehanna University.TMFVolkmanStocks MentionedSoleno TherapeuticsNASDAQ: SLNO$52.25(+32.31%)+$12.76Neurocrine BiosciencesNASDAQ: NBIX$132.48(+0.67%)+$0.88*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.